Nsclc Adenocarcinoma clinical trials

Explore recruiting nsclc adenocarcinoma clinical trials.

Recruiting nsclc adenocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nsclc Adenocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Open-label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Nsclc Adenocarcinoma trials by city

Nsclc Adenocarcinoma clinical trials

Recruiting nsclc adenocarcinoma studies right now

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

AB122 Platform Study

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

A Study of VET3-TGI in Patients With Solid Tumors

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Also recruiting in Europe

A Phase 2 Open-label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies

Nsclc Adenocarcinoma trials by city

Other conditions